Table 2. High-Throughput Glycomic Studies Involving More than 500 Samplesa.
| cohort description | sample no. | technology | manual or automated | data processing tool | ref |
|---|---|---|---|---|---|
| IgG | |||||
| RA | 1099 | MALDI-MS | manual | flexAnalysis | van de Geijn et al. (2009)212 |
| population study | 2298 | UHPLC-FLD, MALDI-MS, LC-MS | manual | GlycoWorkbench | Pucić et al. (2011)*69 |
| population study | 1709 | MALDI-MS | manual | flexAnalysis | Pučić Baković et al. (2013)211 |
| population study | 5117 | UHPLC-FLD | manual | NA | Krištić et al. (2013)70 |
| GWAS | 4095 | UHPLC-FLD, MALDI-MS | manual | NA | Lauc et al. (2013)*71 |
| population study, genetics and epigenetics | 1050 | UHPLC-FLD | manual | NA | Menni, Keser et al. (2013)270 |
| RA | 1800 | LC-MS | manual | Xtractor2D | Bondt et al. (2013)271 |
| population study, GWAS | 1201 | UHPLC-FLD, CGE-LIF, MALDI-MS, LC-MS | manual | flexAnalysis, DataAnalysis, Xtractor2D, glyXtool, glyXalign | Huffman et al. (2014)167 |
| population study | 3515 | UHPLC-FLD | manual | NA | Nikolac Perkovic et al. (2014)272 |
| SLE | 1020 | UHPLC-FLD | manual | NA | Vučković et al. (2015)*273 |
| IBD | 1114 | UHPLC-FLD | manual | NA | Trbojević-Akmačić et al. (2015)*274 |
| population study | 701 | UHPLC-FLD | manual | NA | Yu et al. (2016)275 |
| allergic diseases | 893 | LC-MS | manual | NA | Pezer et al. (2016)276 |
| CRC | 1298 | UHPLC-FLD | manual | NA | Vučković et al. (2016)*277 |
| kidney disfunction | 3274 | UHPLC-FLD | manual | NA | Barrios et al. (2016)278 |
| low back pain | 4511 | UHPLC-FLD | manual | NA | Freidin et al. (2016)279 |
| hypertension | 4757 | UHPLC-FLD | manual | NA | Wang et al. (2016)280 |
| population study | 1826 | LC-MS | manual | Xtractor 2D | Plomp et al. (2017)281 |
| population study, role of hormones | 1010 | HPLC-FLD, UPLC-FLD | manual | NA | Ercan et al. (2017)282 |
| glycosylation regulation | 5243 | LC-MS | manual | DataAnalysis, Xtractor2D | Benedetti et al. (2017)283 |
| GWAS | 8129 | UHPLC-FLD | manual | NA | Shen et al. (2017)284 |
| T2D | 5984 | UHPLC-FLD | manual | NA | Lemmers et al. (2017)285 |
| statin therapy | 4009 | UHPLC-FLD | manual | NA | Keser et al. (2017)286 |
| dyslipidaemia | 598 | UHPLC-FLD | manual | NA | Liu et al. (2018)287 |
| hypertension | 630 | LC-MS | manual | NA | Liu et al. (2018)288 |
| IBD | 3441 | LC-MS | manual | LaCyTools | Šimurina, de Haan, Vučković et al. (2018)*289 |
| population study | 637 | UHPLC-FLD | manual | NA | Russell et al. (2019)*74 |
| hyperuricemia | 635 | UHPLC-FLD | manual | NA | Hou et al. (2019)290 |
| cardiometabolic diseases | 701 | UHPLC-FLD | manual | NA | Wang et al. (2019)291 |
| T2D | 849 | UHPLC-FLD | manual | NA | Li et al. (2019)292 |
| GWAS | 12320 | UHPLC-FLD, LC-MS | manual | NA | Klarić et al. (2020)*268 |
| T2D | 1112 | UHPLC-FLD | manual | NA | Wu et al. (2020)293 |
| T2D | 1815 | UHPLC-FLD | manual | NA | Singh et al. (2020)31 |
| thyroid diseases | 4636 | UHPLC | manual | NA | Martin et al. (2020)77 |
| population study | 13061 | UHPLC-FLD, LC-MS | manual | NA | Štambuk et al. (2020)*29 |
| population study, weight intervention | 3841 | UHPLC-FLD | manual | NA | Greto et al. (2021)*294 |
| hypertension | 3452 | UHPLC-FLD | manual | NA | Kifer et al. (2021)*295 |
| hypertension and T2D | 883 | UHPLC-FLD | manual | NA | Meng et al. (2021)296 |
| perimenopause | 5080 | UHPLC-FLD | manual | NA | Deriš et al. (2022)297 |
| Total Serum Proteins | |||||
| population study | 594 | CE-LIF | manual | GeneMapper | Vanhooren et al. (2010)298 |
| hypertension | 972 | CE-LIF | manual | Genescan | Vilar-Bergua et al. (2015)299 |
| T2D | 1161 | CE-LIF | manual | Genescan | Testa et al. (2015)300 |
| breast cancer | 585 | UHPLC-FLD | automated | NA | Saldova et al. (2017)301 |
| RA | 1562 | MALDI-MS | manual and automated | flexAnalysis, MassyTools, GlycoWorkbench | Reiding et al. (2018)*302 |
| Total Plasma Proteins | |||||
| population study | 1008 | HPLC-FLD | manual | GlycoBase | Knežević et al. (2009)* 27 |
| population study | 1914 | HPLC-FLD | manual | GlycoBase | Knežević et al. (2010)28 |
| GWAS | 2705 | HPLC-FLD | manual | GlycoBase | Lauc et al. (2010)*118 |
| population study, lipidomics | 2035 | HPLC-FLD | manual | NA | Igl, Polašek et al. (2011)303 |
| GWAS | 3533 | HPLC-FLD | manual | GlycoBase | Huffman et al. (2011)*119 |
| metabolic syndrome | 732 | HPLC-FLD | manual | GlycoBase | Lu et al. (2011)304 |
| ADHD and autism | 525 | HPLC-FLD | manual | NA | Pivac et al. (2011)305 |
| medication | 2360 | HPLC-FLD | manual | NA | Saldova et al. (2012)306 |
| HNF1A-MODY | 783 | HPLC-FLD | manual | GlycoBase | Thanabalasingham et al. (2013)307 |
| population study | 2144 | MALDI-MS | manual | DataAnalysis, GlycoWorkbench | Reiding et al. (2017)302 |
| GWAS | 1338 | UHPLC-FLD | manual | NA | Suhre et al. (2017)308 |
| T2D | 505 | UHPLC-FLD | manual | NA | Adua et al. (2017)309 |
| T2D | 1614 | UHPLC-FLD | manual | NA | Keser et al. (2017)310 |
| T2D | 2281 | MALDI-MS | automated | flexAnalysis, MassyTools | Dotz et al. (2018)311 |
| IBD | 3631 | MALDI-MS | manual and automated | MassyTools | Clerc, Novokmet, Dotz et al. (2018)*312 |
| HNF1A-MODY | 989 | UHPLC-FLD | manual | NA | Juszczak et al. (2018)*78 |
| CRC | 1231 | UHPLC-FLD | manual and automated | GlycoBase | Doherty et al. (2018)*313 |
| GWAS | 3811 | UHPLC-FLD | manual | NA | Sharapov et al. (2019)*314 |
| population study | 2396 | HPLC-FLD | manual | Matlab | Ruhaak et al. (2020)315 |
| metformin and statin use in T2D | 3333 | MALDI-MS | automated | DataAnalysis | Singh et al. (2020)31 |
| cardiometabolic risk | 3140 | UHPLC-FLD | manual | NA | Wittenbecher et al. (2020)76 |
| GWAS | 4802 | UHPLC-FLD | manual | NA | Sharapov et al. (2021)*316 |
| T2D | 506 | UHPLC-FLD | manual | NA | Edua et al. (2021)317 |
| diabetes | 610 | UHPLC-FLD | manual | GlycoStore | Cvetko et al. (2021)318 |
| T2D complications | 3333 | MALDI-MS, FTICR-MS | manual and automated | MassyTools | Memarian et al. (2021)319 |
| IgG and Total Plasma Proteins | |||||
| kidney disease in T1D | 818 | UHPLC-FLD | manual | NA | Bermingham et al. (2017)75 |
| evaluation of glycomics normalization methods | 5139 | UHPLC-FLD, MALDI-MS, LC-MS | manual | DataAnalysis, GlycoWorkbench | Benedetti et al. (2020)133 |
| age-related macular degeneration | 2835 | HPLC-FLD, UHPLC-FLD | manual | NA | Bućan et al. (2022)320 |
| IgA | |||||
| RA | 1800 | MALDI-MS | manual | MassyTools | Bondt et al. (2017)321 |
| Antigen-Specific IgG | |||||
| RA | 703 | LC-MS | manual | LaCyTools | Bondt et al. (2018)222 |
| COVID-19 | 650 | LC-MS | manual | LaCyTools | Pongracz et al. (2021)*216 |
| viral infections | 2 × 400 | LC-MS | manual | Skyline | Larsen et al. (2021)217 |
| Apolipoprotein CIII | |||||
| population study | 771 | MALDI-MS | automated | MassyTools | Demus et al. (2021)322 |
| HMOs | |||||
| infant morbidity and inflammation | 659 | LC-MS | manual | MassHunter Qualitative Analysis | Jorgensen et al. (2021)*323 |
| AGP | |||||
| diabetes | 635 | LC-MS | manual | LaCyTools | Tijardović et al. (2022)324 |
| Tf and IgG | |||||
| GWAS | 1900 | UHPLC-FLD | manual | NA | Landini et al. (2022)*325 |
a
Studies denoted with an asterisk were highlighted in the main body of the manuscript. RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; IBD, inflammatory bowel disease; CRC, colorectal cancer; T2D, type 2 diabetes; ADHD, attention-deficit hyperactivity disorder; HNF1A-MODY, hepatocyte nuclear factor 1α maturity-onset diabetes of the young; T1D, type 1 diabetes; COVID-19, coronavirus disease 2019.